The problem to solve
Effector-cell access to solid tumors and functional persistence in suppressive microenvironments remain core bottlenecks.
PLATFORM 04
Immune-cell Delivery Enhancement
Exploring a delivery entry point for solid-tumor cell therapy through multicellular synergy and chemical conjugation.
Platform approach
Cells with tumor-homing and microenvironment-interaction capacity serve as carriers, with controlled linkage organizing local synergistic units.
Core functional modules
Cell-linking systemEffector-function retentionSolid-tumor infiltrationMicroenvironment synergy
Evidence path
- Linkage stability and cell health
- In vitro migration and function
- In vivo infiltration and tumor control
- IP and quality framework
DISCLOSURE BOUNDARY
Communicating platform value without disclosing reproducible details
Public pages do not disclose molecules, targets, formulation parameters, device parameters, raw data or unpublished IP structures. Deeper discussion proceeds through Partner Access.
BUILD THE NEXT VALUE INFLECTION
Turn the next asset into decision-grade evidence
Connect with BM Pharma on delivery platforms, co-development, translation and strategic partnerships.